Latin America Glucagon-like Peptide-1 (GLP-1) Agonists - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The latin america glucagon-like peptide-1 agonists market size is estimated at USD 2.91 billion in 2026, and is expected to reach USD 4.33 billion by 2031, at a CAGR of 8.24% during the forecast period (2026-2031). This report is Segmented by Drug (Exenatide, and More), Route of Administration (Injectable Pens, and More), Indication (Type 2 Diabetes, and More), Distribution Channel (Hospital Pharmacies, and More), End User (Hospitals & Specialty Diabetes Centers, and More), and Geography (Brazil, Mexico, and More). The Market Forecasts are Provided in Terms of Value (USD).

Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market Trends and Insights

Rising T2D And Obesity Prevalence Fuels Baseline Demand

Adult diabetes cases in South and Central America climbed from 32 million in 2021 to 35.4 million in 2024 and are projected to reach 51.5 million by 2050, creating a vast patient pool for the Latin America GLP-1 agonists market. Mexico's 2023 documented 38.9 percent of obesity prevalence among adults, while 37.3 percent of the population is classified as overweight or obese, creating a high patient pool of individuals. In Brazil, 16.6 million residents carry a diabetes diagnosis, yet fewer than 40% achieve HbA1c targets under public care models. Better adherence profiles for once-weekly GLP-1 agents therefore present a clinical upgrade over older sulfonylureas. Regional cardiovascular-mortality data further underline the urgency of therapies that simultaneously address glycemia, weight, and cardiometabolic risk.

Physician Shift Toward Once-Weekly And Dual-Incretin Therapies

Brazilian and Mexican endocrinologists report 30%-40% higher 12-month persistence for once-weekly semaglutide or dulaglutide compared with daily liraglutide. Tirzepatide’s 2.0%-2.5% mean HbA1c reduction in SURPASS studies outperformed semaglutide by roughly 0.5 percentage points, prompting Mexico’s regulator to authorize the drug for obesity in 2024. Survey data from Brazil showed 62% of specialists preferring weekly regimens for patients with prior adherence issues. Private insurers in São Paulo and Rio logged a 45% annual jump in once-weekly GLP-1 scripts in 2025, showing that convenience translates to volume gains once costs moderate.

High Therapy Cost And Patchy Public Coverage

Monthly branded semaglutide costs reach BRL 1,200 (USD 240) in Brazil - about 80% of the minimum wage - placing it out of reach for many SUS beneficiaries. Mexico’s IMSS serves less than 5,000 GLP-1 patients annually via exception pathways, despite more than 12 million diabetics. Argentina and Colombia apply strict prior-authorization hurdles that lengthen initiation and depress uptake, effectively confining large segments of the Latin America GLP-1 agonists market to private payers.

Other drivers and restraints analyzed in the detailed report include:

• Gradual Reimbursement Expansion In Brazil, Colombia, And Beyond
• Local Manufacturing And Fill-Finish Investments Lower Supply Risk
• Global Supply Shortages And Allocation Caps

Segment Analysis

Semaglutide captured 51.35% of the Latin America GLP-1 agonists market in 2025 thanks to once-weekly convenience and robust SUSTAIN and STEP data. Tirzepatide’s 12.12% forecast CAGR reflects its dual receptor mechanism and superior weight-loss performance, with COFEPRIS granting an obesity label in 2024. Dulaglutide maintains a steady user base among Brazilian private insurers who favor its auto-injector design, while liraglutide’s daily-injection regimen is losing ground to longer-acting rivals. Biosimilar pipelines will accelerate after semaglutide’s Brazilian patent expiry in March 2026, as Fiocruz-EMS aims for 2 million annual pens by 2028. Oral semaglutide remains a niche alternative for needle-averse patients, though fasting-administration requirements curtail adherence.

In value terms, tirzepatide could command 30% of the drug class by 2031 if HTA bottlenecks clear and price parity tightens. Exenatide and lixisenatide remain relegated to cost-sensitive tender lots, preserving minimal but steady volume. The Latin America GLP-1 agonists market size for pipeline and biosimilar entrants is projected to grow quickly once public sectors secure 30%-40% list-price discounts.

Injectable pens controlled 91.68% revenue in 2025 thanks to pre-filled accuracy, once-weekly scheduling, and audible dose cues that benefit low-vision patients. Brazil’s telemedicine rule accelerates pen adoption because video-based injection training is easily delivered. However, oral tablets are projected to post a 10.35% CAGR as private plans expand Rybelsus coverage and as potential biosimilar competition narrows cost gaps. If oral semaglutide prices fall below USD 150 per month once local licensees enter, tablets could reach a 15% share by 2031.

Pen innovation continues: Novo Nordisk’s FlexTouch and Eli Lilly’s KwikPen incorporate tactile feedback that reduces dosing errors. Mexico’s labeling rules mandate Spanish instructions and tactile dose indicators, raising costs yet boosting patient safety. The Latin America GLP-1 agonists market size for pens still dwarfs tablets, but oral formats will increasingly attract first-line therapy seekers who dislike injections.

Complete Report Scope:

• By Drug
  • Exenatide
  • Liraglutide
  • Lixisenatide
  • Dulaglutide
  • Semaglutide
  • Tirzepatide (dual GIP/GLP-1)
  • Pipeline & Biosimilar/Generic GLP-1s
• By Route of Administration
  • Injectable Pens
  • Oral Tablets
• By Indication
  • Type 2 Diabetes
  • Obesity / Weight-management
  • Cardiovascular & Renal Risk Reduction
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Chain Pharmacies
  • E-Commerce / Tele-pharmacy
• By End User
  • Hospitals & Specialty Diabetes Centers
  • Private Endocrinology Clinics
  • Homecare / Self-administration
• By Geography
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

List of Companies Covered in this Report:

• Amgen
• AstraZeneca
• Biocon
• Biomm S.A.
• Boehringer Ingelheim International GmBH
• Bristol-Myers Squibb
• Eli Lilly and Company
• Eurofarma
• Glenmark Pharmaceuticals
• Hypera S.A.
• Novartis
• Novo Nordisk
• Pfizer
• Probiomed
• Sanofi
• Takeda Pharmaceuticals
• Teva Pharmaceutcials Limited
• Torrent Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support